A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product...
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a...
Cadrenal Therapeutics is developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner), to prevent heart attacks, strokes, and deaths due to blood clots in patients with certain rare medical conditions who require chronic anticoagulation....
Hydreight Technologies Inc. is building the largest mobile clinic network in the United States. Its proprietary, fully integrated platform hosts a network of over 2500 nurses, over 100 doctors and a pharmacy network across 50 states. The platform includes a built-in,...
During this fireside chat we welcome Delcath Systems CEO Gerard Michel. Delcath is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. This Fireside Chat was recorded during the Lytham Partners Fall 2023 Investor...
During this fireside chat we welcome Aytu BioPharma CEO Josh Disbrow. Aytu is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. This Fireside Chat was recorded during the Lytham Partners Fall...
This panel explores how innovative technologies, business models, and strategies are reshaping healthcare delivery, improving patient outcomes, and creating exciting #investment opportunities. Speakers include: Dr. Lisa Crossley, CEO at Reliq Health Technologies,...
This panel explores the dynamic realm of leading-edge technologies within the fertility market. Speakers include Steve Shum, CEO at INVO Bioscience and David Wolf, CEO at Hamilton Thorne Ltd. This KOL Panel was recorded during the Lytham Partners Fall 2023 Investor...
In this panel companies discuss developments in the broader market, as well as their unique late-stage drugs looking to address cardiac-based indications. Panelists include Quang Pham, Chairman & CEO at Cadrenal Therapeutics and Craig Fraser, CEO at Windtree...
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative...
Syra Health is a healthcare company addressing some of healthcare's most significant challenges by providing innovative services and technology solutions. Syra Health specializes in behavioral and mental health, digital health, and population health. Syra Health's...
Retrospective Comparison of Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (17 and 9.9 months, respectively; p=0.006) NEW YORK, Oct. 16, 2023 -- Delcath Systems,...
SARASOTA, Fla., Oct. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the...
Patent Application Filed with Potential to Extend Ameluz® Protection to 2043WOBURN, MA / ACCESSWIRE / October 10, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of...
NEW YORK, Oct. 10, 2023 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference...
PONTE VEDRA, Fla., Oct. 9, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths...
ENGLEWOOD, CO / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings...
GARDNER, Mass., Oct. 9, 2023 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that Dr. Joe Forkey, Chief Executive Officer, will present...
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global...
PORTLAND, Maine, Oct. 05, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
WOBURN, MA / ACCESSWIRE / October 5, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced management will deliver a company presentation and...
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global...
Revenues Increased 101% to 108% Over the Prior-Year QuarterAffirms Guidance for Full-Year Revenue Growth of at Least 25% over 2022WOBURN, MA / ACCESSWIRE / October 4, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company...
NEW YORK, Oct. 3, 2023 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the Roth MKM Healthcare Opportunities Conference in New York. Delcath CEO,...
SARASOTA, Fla., Sept. 29, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced that its special meeting of shareholders on September 29, 2023 (the "Special Meeting") was convened and then adjourned, without conducting any...
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction...
Conference Call Scheduled for today, September 28, 2023, at 5:00pm ET GARDNER, Mass., Sept. 28, 2023 -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries,...
SARASOTA, Fla., Sept. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the...
Q4 2023 net revenue of $30.7 million; Adjusted EBITDA of $7.7 millionRecord Q4 2023 total prescriptions increased 32% compared to Q4 2022Rx Segment net revenue of $23.3 million and Adjusted EBITDA of $8.3 million in Q4 2023Company to host conference call today at...
NEW YORK, Sept. 27, 2023 -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, in the form of...
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction...
CARMEL, Ind., Sept. 26, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...
GARDNER, Mass., Sept. 25, 2023 -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that it has scheduled a conference call to...
ENGLEWOOD, CO / September 21, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the...
CARMEL, Ind., Sept. 21, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial...
Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform, in addition to potential success fees, milestones, and royalties. JUPITER, Fla., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc....
ENGLEWOOD, CO / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow, and CFO, Mark Oki, will be will be participating in the...
Carlsbad, Calif., Sept. 13, 2023 -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV:ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced today that it is in full commercial...
CARMEL, Ind., Sept. 13, 2023 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that...
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction...
CARMEL, Ind., Sept. 12, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...
Independent Investigator Study Compared Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (516 and 301 days, respectively; p=0.006) NEW YORK, Sept. 11, 2023 --...
WINTER SPRINGS, Fla., Sept. 06, 2023 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences. Iradimed management is scheduled to participate in investor meetings at the H.C....
NEW YORK, Sept. 5, 2023 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference. Delcath CEO,...
Tecarfarin is the only known Novel Vitamin K Antagonist in Development PONTE VEDRA, Fla., Sept. 5, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant...
NEW YORK, Sept. 1, 2023 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 million through the exercise of all the...
NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots...
WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the...
PORTLAND, Maine, Aug. 29, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
A Retrospective Comparative Study of SIRT and CS-PHP for Liver Targeted Therapy of Patients with Metastatic Uveal Melanoma NEW YORK, Aug. 29, 2023 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and...